{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:59:41Z","timestamp":1793145581305,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The Dermatology Quality Life Index (DLQI) has seen widespread use as a health-related quality of life measure for a variety of dermatological diseases. The purpose of this study was to estimate the minimal important difference (MID) on the DLQI for patients with chronic idiopathic urticaria (CIU).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Data from 2 Phase III clinical trials of patients (N = 476 for Study A; N = 468 for Study B) with CIU were analyzed separately to estimate the MID for the DLQI for these populations. Both distributional based and anchor based approaches were used for deriving estimates. The anchor based approach relied upon patient self assessments of pruritus severity; the distributional based approaches relied upon estimating the standard error of measurement, as well as one-half the standard deviation of the DLQI from each study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The distributional approaches resulted in estimates of MID ranging from 2.24 to 3.10 for the two studies. The anchor based approach resulted in estimates of 3.21 and 2.97 for the two studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>An MID for the DLQI in the range of 2.24 to 3.10 is recommended in interpreting results for patients with CIU.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7525-3-36","type":"journal-article","created":{"date-parts":[[2005,5,20]],"date-time":"2005-05-20T18:13:47Z","timestamp":1116612827000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Minimal Important Difference (MID) of the Dermatology Life Quality Index (DLQI): Results from patients with chronic idiopathic urticaria"],"prefix":"10.1186","volume":"3","author":[{"given":"Richard","family":"Shikiar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gale","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Leahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D","family":"Lennox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,5,20]]},"reference":[{"key":"187_CR1","first-page":"33","volume":"46","author":"TJ Ryan","year":"1991","unstructured":"Ryan TJ: Disability in dermatology. Br J Hosp Med 1991, 46: 33\u201336.","journal-title":"Br J Hosp Med"},{"key":"187_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/0277-9536(85)90021-8","volume":"20","author":"S Jowett","year":"1985","unstructured":"Jowett S, Ryan T: Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985, 20: 425\u2013429. 10.1016\/0277-9536(85)90021-8","journal-title":"Soc Sci Med"},{"key":"187_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0190-9622(89)70007-4","volume":"20","author":"IH Ginsburg","year":"1989","unstructured":"Ginsburg IH, Link BG: Feeling of stigmatization in patients with psoriasis. J Am Acad Dermatol 1989, 20: 53\u201363.","journal-title":"J Am Acad Dermatol"},{"key":"187_CR4","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1046\/j.1365-2133.2001.04183.x","volume":"144","author":"CR Touw","year":"2001","unstructured":"Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY: Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001, 144: 967\u2013972. 10.1046\/j.1365-2133.2001.04183.x","journal-title":"Br J Dermatol"},{"issue":"5","key":"187_CR5","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1081-1206(10)62515-X","volume":"84","author":"HS Nelson","year":"2000","unstructured":"Nelson HS, Reynolds R, Mason J: Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000,84(5):517\u2013522.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"187_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0091-6749(99)70091-6","volume":"104","author":"AF Finn Jr","year":"1999","unstructured":"Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J: A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999, 104: 1071\u20131078.","journal-title":"J Allergy Clin Immunol"},{"issue":"Suppl 52","key":"187_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1046\/j.1365-2133.1998.1390s2026.x","volume":"139","author":"E Grosshans","year":"1998","unstructured":"Grosshans E, Marks R, Mascaro JM, Torras H, Meynadier J, Alirezai M, Finlay AY, Soto P, Poncet M, Verschoore M, Clucas A: Evaluation of clinical efficacy and safety of adapalene 0.1% gel versus tretinoin 0.025% gel in the treatment of acne vulgaris, with particular reference to the onset of action and impact on quality of life. Br J Dermatol 1998,139(Suppl 52):26\u201333. 10.1046\/j.1365-2133.1998.1390s2026.x","journal-title":"Br J Dermatol"},{"key":"187_CR8","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1365-2133.1995.tb05019.x","volume":"132","author":"AY Finlay","year":"1995","unstructured":"Finlay AY, Coles EC: The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995, 132: 236\u2013244.","journal-title":"Br J Dermatol"},{"key":"187_CR9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use. Clin Exp Dermatol 1994, 19: 210\u2013216.","journal-title":"Clin Exp Dermatol"},{"key":"187_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/009286150303700105","volume":"37","author":"JA Sloan","year":"2003","unstructured":"Sloan JA, Symonds T, Vargas-Chanes D, Friedly B: Practical guidelines for assessing the clinical significance of heath related quality of life changes within clinical trials. Drug Inf J 2003, 37: 23\u201331.","journal-title":"Drug Inf J"},{"key":"187_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0895-4356(94)90036-1","volume":"47","author":"EF Juniper","year":"1994","unstructured":"Juniper EF, Guyatt GH, Willan A, Griffith LE: Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994, 47: 81\u201387. 10.1016\/0895-4356(94)90036-1","journal-title":"J Clin Epidemiol"},{"key":"187_CR12","first-page":"333","volume":"7","author":"EF Juniper","year":"1997","unstructured":"Juniper EF: The value of quality of life in asthma. Eur Respir Rev 1997, 7: 333\u2013337.","journal-title":"Eur Respir Rev"},{"key":"187_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0091-6749(98)70048-X","volume":"102","author":"EF Juniper","year":"1998","unstructured":"Juniper EF: Quality of life questionnaires: does statistically significant = clinically important? J Allergy Clin Immunol 1998, 102: 16\u201317.","journal-title":"J Allergy Clin Immunol"},{"key":"187_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1097\/00005650-199905000-00006","volume":"37","author":"KW Wyrwich","year":"1999","unstructured":"Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD: Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999, 37: 469\u2013478. 10.1097\/00005650-199905000-00006","journal-title":"Med Care"},{"key":"187_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S0895-4356(99)00071-2","volume":"52","author":"KW Wyrwich","year":"1999","unstructured":"Wyrwich KW, Tierney WM, Wolinsky FD: Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999, 52: 861\u2013873. 10.1016\/S0895-4356(99)00071-2","journal-title":"J Clin Epidemiol"},{"key":"187_CR16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/00005650-200305000-00004","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman GR, Sloan JA, Wyrwich KW: Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003, 41: 582\u2013592. 10.1097\/00005650-200305000-00004","journal-title":"Med Care"},{"key":"187_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/BF01593882","volume":"4","author":"CA McHorney","year":"1995","unstructured":"McHorney CA, Tarlov AR: Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res 1995, 4: 293\u2013307. 10.1007\/BF01593882","journal-title":"Qual Life Res"},{"key":"187_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1023\/A:1015276414526","volume":"11","author":"D Cella","year":"2002","unstructured":"Cella D, Hahn EA, Dineen K: Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res 2002, 11: 207\u2013221. 10.1023\/A:1015276414526","journal-title":"Qual Life Res"},{"key":"187_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.2165\/00019053-199712060-00002","volume":"12","author":"GH Guyatt","year":"1997","unstructured":"Guyatt GH, Jaeschke RJ: Reassessing quality-of-life instruments in the evaluation of new drugs. Pharmacoeconomics 1997, 12: 621\u2013626.","journal-title":"Pharmacoeconomics"},{"key":"187_CR20","volume-title":"SF-36 Health Survey: Manual and Interpretation Guide","author":"JE Ware","year":"1993","unstructured":"Ware JE, Snow KK, Kosinski MK, Gandek B: SF-36 Health Survey: Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center; 1993."},{"key":"187_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1477-7525-1-53","volume":"1","author":"R Shikiar","year":"2003","unstructured":"Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA: Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 2003, 1: 53. 10.1186\/1477-7525-1-53","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 2","key":"187_CR22","first-page":"50","volume":"147","author":"FA Khilji","year":"2002","unstructured":"Khilji FA, Gonzalez M, Finlay AY: Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002,147(Suppl 2):50.","journal-title":"Br J Dermatol"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7525-3-36.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T23:11:40Z","timestamp":1630451500000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/1477-7525-3-36"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,20]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["187"],"URL":"https:\/\/doi.org\/10.1186\/1477-7525-3-36","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,20]]},"assertion":[{"value":"1 March 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"36"}}